10x Genomics, Inc. TXG Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s deferred revenue?
- 10x Genomics, Inc. (TXG) reported deferred revenue of $24.34M in Q1 2026.
- How has 10x Genomics, Inc.'s deferred revenue changed year-over-year?
- 10x Genomics, Inc.'s deferred revenue increased by 16.2% year-over-year, from $20.95M to $24.34M.
- What is the long-term trend for 10x Genomics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s deferred revenue has grown at a 39.8% compound annual growth rate (CAGR), from $4.47M to $23.9M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.